William D. Turner - 07 Feb 2022 Form 4 Insider Report for Sierra Oncology, Inc.

Role: Chief Reg & Tech Ops Officer
Signature: /s/ William D. Turner / By: Mary Christina Thomson, Attorney-In-Fact
Issuer symbol: N/A
Transactions as of: 07 Feb 2022
Net transactions value: -$202,725
Form type: 4
Filing time: 08 Feb 2022, 15:03:34 UTC
Previous filing: 28 Jan 2022
Next filing: 14 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRRA	Common Stock	Options Exercise	$120,500	+10,000		$12.05	10,000	07 Feb 2022	Direct
transaction	SRRA	Common Stock	Sale	$323,225	-10,000	-100%	$32.32	0	07 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRRA	Stock Option (Right to Buy)	Options Exercise	$0	+10,000		$0.000000^*	0	07 Feb 2022	Common Stock	10,000	$12.05	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
F2	On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.